Genetics and variability in opioid response

The human genome project has revealed data on genomic variation which may influence the pharmacological responses. In pain therapy, the genetic background influencing the efficacy of opioid therapy is of special interest. Screening for variations in expression of drug metabolizing enzymes has been s...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pain 2005-04, Vol.9 (2), p.101-104
Main Authors: Stamer, Ulrike M., Bayerer, Bettina, Stüber, Frank
Format: Article
Language:English
Subjects:
Analgesics, Opioid - metabolism
Analgesics, Opioid - pharmacology
Codeine
Cytochrome P-450 CYP2D6 - genetics
Drug metabolizing enzymes
Drug Resistance - genetics
Humans
Opioid receptors
Pharmacogenetics
Receptors, Opioid - genetics
Tramadol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The human genome project has revealed data on genomic variation which may influence the pharmacological responses. In pain therapy, the genetic background influencing the efficacy of opioid therapy is of special interest. Screening for variations in expression of drug metabolizing enzymes has been suggested as a potential tool for improving patient therapy. CYP2D6 genetic variability is supposed to be a major factor of adverse drug reaction, possibly influencing hospital stay and total costs. Further candidate genes involved in pain perception, pain processing and pain management like opioid receptors, transporters and other targets of pharmacotherapy are under investigation. Aspects of genetic differences influencing efficacy, side effects and adverse outcome of pharmacotherapy will be of importance for future pain management.
ISSN:1090-3801
1532-2149
DOI:10.1016/j.ejpain.2004.05.008